Total Payments
$2.7M
2024 Payments
$233,230
Companies
40
Transactions
2,314
Medicare Patients
1,726
Medicare Billing
$245,497
Payment Breakdown by Category
Other$1.4M (54.0%)
Consulting$807,300 (30.1%)
Travel$281,783 (10.5%)
Research$91,764 (3.4%)
Food & Beverage$42,278 (1.6%)
Education$9,816 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 434 | 52.5% |
| Consulting Fee | $807,300 | 187 | 30.1% |
| Travel and Lodging | $281,783 | 457 | 10.5% |
| Unspecified | $91,764 | 168 | 3.4% |
| Food and Beverage | $42,278 | 1,056 | 1.6% |
| Grant | $33,600 | 1 | 1.3% |
| Education | $9,816 | 7 | 0.4% |
| Honoraria | $4,150 | 4 | 0.2% |
Payments by Type
General
$2.6M
2,146 transactions
Research
$91,764
168 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $609,696 | 489 | $0 (2024) |
| Biogen, Inc. | $515,691 | 337 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $332,153 | 460 | $0 (2024) |
| EMD Serono, Inc. | $256,033 | 202 | $0 (2024) |
| Genentech USA, Inc. | $204,939 | 161 | $0 (2024) |
| TG Therapeutics, Inc. | $131,922 | 86 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $127,615 | 34 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $77,908 | 56 | $0 (2024) |
| Celgene Corporation | $72,755 | 101 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $60,328 | 50 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $233,230 | 255 | TG Therapeutics, Inc. ($89,132) |
| 2023 | $247,098 | 233 | EMD Serono, Inc. ($58,800) |
| 2022 | $302,243 | 274 | Biogen, Inc. ($107,957) |
| 2021 | $214,543 | 187 | Biogen, Inc. ($64,026) |
| 2020 | $222,735 | 184 | Biogen, Inc. ($73,688) |
| 2019 | $508,303 | 431 | GENZYME CORPORATION ($98,779) |
| 2018 | $440,087 | 333 | GENZYME CORPORATION ($156,994) |
| 2017 | $509,565 | 417 | GENZYME CORPORATION ($237,327) |
All Payment Transactions
2,314 individual payment records from CMS Open Payments — Page 1 of 93
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,933.00 | General |
| Category: Neurology | ||||||
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,593.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,088.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: PAIN | ||||||
| 12/16/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $25.63 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/11/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $2.28 | General |
| Category: Neuroscience | ||||||
| 12/10/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $5.86 | General |
| Category: PAIN | ||||||
| 12/09/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,088.00 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,130.00 | General |
| 12/05/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $45.75 | General |
| 11/27/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.85 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $51.75 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $33.07 | General |
| Category: Neurology | ||||||
| 11/22/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $4.62 | General |
| Category: PAIN | ||||||
| 11/21/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $861.44 | General |
| Category: Neurology | ||||||
| 11/21/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $604.02 | General |
| Category: Neurology | ||||||
| 11/21/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $416.97 | General |
| Category: Neurology | ||||||
| 11/21/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $352.12 | General |
| Category: Neurology | ||||||
| 11/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.66 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $29.78 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 11/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $930.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $25,706 | 48 |
| KESIMPTA Study Related Review Article Writing Support | Novartis Pharmaceuticals Corporation | $20,939 | 1 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $9,237 | 22 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $5,781 | 30 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,211 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,614 | 7 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $2,796 | 11 |
| vsMS KH - 161101990 (Patient Survey) | GENZYME CORPORATION | $2,607 | 3 |
| An Extension Protocol for Multiple Sclerosis patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $2,126 | 9 |
| A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RMS TO INVESTIGATE CHANGES IN IMMUNE PHENOTYPE BIOMARKERS AFTER TREATMENT WITH 05MG FINGOLIMOD FLUENT | Novartis Pharmaceuticals Corporation | $1,875 | 1 |
| vsMS Patient Survey | GENZYME CORPORATION | $1,680 | 5 |
| CAMMS324 - CARE-MS II and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $1,673 | 5 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,487 | 3 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $1,339 | 4 |
| MS Patient Survey | GENZYME CORPORATION | $1,269 | 2 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409) | GENZYME CORPORATION | $892.80 | 1 |
| vsMS MS Patient Survey - KH - 161101990 | GENZYME CORPORATION | $628.25 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Scerlosis Patients Who Participated in Gen | GENZYME CORPORATION | $472.94 | 1 |
| CAMMS323 - CARE-MS I and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $458.92 | 3 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Sclerosis Patients Who Participated in Gen | GENZYME CORPORATION | $446.67 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study O | GENZYME CORPORATION | $446.67 | 1 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study One (CARE | GENZYME CORPORATION | $446.67 | 1 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $213.06 | 2 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study T | GENZYME CORPORATION | $187.06 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409)Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study T | GENZYME CORPORATION | $120.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 396 | 548 | $153,466 | $56,826 |
| 2022 | 5 | 394 | 567 | $157,664 | $62,494 |
| 2021 | 5 | 439 | 605 | $156,145 | $65,232 |
| 2020 | 6 | 497 | 665 | $163,168 | $60,945 |
Total Patients
1,726
Total Services
2,385
Medicare Billing
$245,497
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 273 | 409 | $120,655 | $45,573 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 58 | $12,702 | $4,357 | 34.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $6,910 | $2,250 | 32.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 37 | $5,550 | $2,210 | 39.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,736 | $2,029 | 30.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 11 | $913.00 | $406.95 | 44.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 266 | 420 | $119,700 | $48,075 | 40.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 82 | $17,302 | $6,576 | 38.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $8,020 | $3,093 | 38.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $6,902 | $2,512 | 36.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 28 | $5,740 | $2,237 | 39.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 272 | 410 | $113,160 | $47,764 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 97 | 116 | $23,664 | $9,662 | 40.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 24 | $9,336 | $3,799 | 40.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 39 | $7,761 | $3,098 | 39.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 16 | $2,224 | $909.12 | 40.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 298 | 443 | $118,281 | $43,955 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 126 | 139 | $27,522 | $9,550 | 34.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 19 | $7,163 | $3,084 | 43.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 24 | 34 | $4,556 | $1,906 | 41.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 19 | $3,667 | $1,585 | 43.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 11 | 11 | $1,979 | $865.23 | 43.7% |
About Barry Singer
Barry Singer is a Neurology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932210671.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Barry Singer has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $233,230 received in 2024. These payments were reported across 2,314 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Singer has provided services to 1,726 Medicare beneficiaries, totaling 2,385 services with total Medicare billing of $245,497. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Saint Louis, MO
- Active Since 08/31/2006
- Last Updated 02/22/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1932210671
Products in Payments
- LEMTRADA (Drug) $373,399
- AUBAGIO (Drug) $257,179
- VUMERITY (Drug) $170,942
- GILENYA (Drug) $167,286
- OCREVUS (Biological) $140,312
- BRIUMVI (Drug) $122,623
- ZEPOSIA (Drug) $105,849
- TYSABRI (Biological) $95,538
- Mavenclad (Drug) $75,897
- Ocrevus (Biological) $66,831
- Mavenclad (Biological) $65,637
- TECFIDERA (Drug) $60,304
- MAYZENT (Drug) $60,279
- KESIMPTA (Drug) $53,972
- COPAXONE (Drug) $41,310
- MAVENCLAD (Drug) $36,334
- ARZERRA (Drug) $32,749
- Ozanimod (Drug) $32,531
- Non-Covered Product (Drug) $28,408
- Rebif (Biological) $27,180
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Saint Louis
Dr. Mark Tullman, M.d, M.D
Neurology — Payments: $2.1M
Neurology $2.1M
Dr. Robert Naismith, Md, MD
Neurology — Payments: $774,163
Neurology $774,163
Dr. Barbara Green, Md, MD
Neurology — Payments: $597,464
Neurology $597,464
Dr. Arun Varadhachary, Md, MD
Neurology — Payments: $373,665
Neurology $373,665
Dr. Anne Cross, Md, MD
Neurology — Payments: $270,789
Neurology $270,789
Pratap Chand, Md, MD
Neurology — Payments: $210,058
Neurology $210,058